Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expanding Horizons: Benda Subsidiary Developing Potential AIDS Vaccine (China)

This article was originally published in PharmAsia News

Executive Summary

China's Benda Pharmaceutical has announced its SiBiono subsidiary will work to produce a gene therapy treatment for AIDS. SiBiono is teaming up with DNAVEC, a Japanese research institute, to develop the prospective therapy. DNAVEC has agreed to give SiBiono the Chinese development and distribution rights to its experimental gene therapy vaccine SeV-Gag. This agreement would provide SiBiono entry into China's $14 billion AIDS treatment market. In return, SiBiono will allow DNAVEC access to its gene therapy platform for the production of SeV-Gag. As part of the agreement, SiBiono will also be responsible for all trials and approval processes of the drug in China. Benda is one of the country's top producers of both traditional and Western medicines. It is also the first company in the world to market gene therapy as a method for fighting cancer. (Click here for more

You may also be interested in...



Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel